{"id":2994,"date":"2022-11-18T13:53:03","date_gmt":"2022-11-18T12:53:03","guid":{"rendered":"https:\/\/genmico.unizar.es\/?page_id=2994"},"modified":"2023-02-22T11:08:28","modified_gmt":"2023-02-22T10:08:28","slug":"era4tb","status":"publish","type":"page","link":"https:\/\/genmico.unizar.es\/en\/d2amr-antimicrobials\/era4tb\/","title":{"rendered":"ERA4TB"},"content":{"rendered":"<p>[vc_row][vc_column width=&#8221;1\/4&#8243; css=&#8221;.vc_custom_1610458272385{margin-top: -24px !important;}&#8221;][vc_column_text]<\/p>\n<aside id=\"enhancedtextwidget-3\" class=\"widget-odd widget-3 widget widget_text enhanced-text-widget\">\n<h3 class=\"widget-title\">ANTIMICROBIALS<\/h3>\n<\/aside>\n<p>[\/vc_column_text][vc_wp_custommenu nav_menu=&#8221;33&#8243;][vc_single_image image=&#8221;2998&#8243;][\/vc_column][vc_column width=&#8221;3\/4&#8243;]<h2 style=\"text-align:left;font-size:24px;line-height:28px;\" class=\"tm-custom-heading \" >ERA4TB project<\/h2>\n[vc_column_text]The ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative dedicated to accelerating the development of new TB treatment regimens, co-funded by the European programme H2020.<br \/>\nThe ERA4TB consortium consists of 31 partners from the European Union and the United States, including major global players in the fight against tuberculosis infection, pharmaceutical companies and academia.<\/p>\n<p>ERA4TB started in 2020 and will run for six years, at the end of which the consortium expects to have two or more new, safe, effective and potentially treatment-shortening combination regimens ready for Phase II clinical evaluation.<\/p>\n<p>For more information: <a href=\"https:\/\/era4tb.org\/\">https:\/\/era4tb.org\/<\/a><\/p>\n<p>The Antimicrobials group of the University of Zaragoza is leading a work package dedicated to the in vitro characterisation of the new drug candidates against tuberculosis and its resistant strains. As a partner of the ERA4TB consortium, the University of Zaragoza implements the methodology, based on hollow fibre bioreactors, to study the efficacy of potential drug combinations.[\/vc_column_text][vc_empty_space]<h2 style=\"text-align:left;font-size:24px;line-height:28px;\" class=\"tm-custom-heading \" >Partners of the Work Package 2:<\/h2>\n[vc_row_inner][vc_column_inner width=&#8221;1\/3&#8243;]<ul class=\"tm-list tm-list-style-icon tm-list-icon-color-skincolor tm- tm-icon-skincolor tm-list-textsize- tm-list-icon-library-fontawesome\"><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Institut Pasteur de Paris<\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Universidad de Zaragoza<\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Institut Pasteur<\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Forschungszentrum Borstel \u2013 Leibniz Lung Center <\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Universit\u00e4tsklinikum K\u00f6ln A\u00f6R <\/span><\/li><\/ul>[\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243; tm_responsive_css=&#8221;46881380|colbreak_no|||||||||colbreak_no|||||||||colbreak_no|-30px|||||||||colbreak_no|||||||||&#8221;]<ul class=\"tm-list tm-list-style-icon tm-list-icon-color-skincolor tm- tm-icon-skincolor tm-list-textsize- tm-list-icon-library-fontawesome\"><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Universita degli Studi di Padova<\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Universit\u00e0 degli Studi di Pavia <\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">BIOASTER Fondation de Cooperation Scientifique<\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Glaxosmithkline Investigaci\u00f3n y Desarrollo<\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Evotec International GmbH<\/span><\/li><\/ul>[\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243; tm_responsive_css=&#8221;49199131|colbreak_no|||||||||colbreak_no|||||||||colbreak_no|-30px|||||||||colbreak_no|||||||||&#8221;]<ul class=\"tm-list tm-list-style-icon tm-list-icon-color-skincolor tm- tm-icon-skincolor tm-list-textsize- tm-list-icon-library-fontawesome\"><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Janssen Pharmaceutica NV<\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">Bill & Melinda Gates Foundation <\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">The Global Alliance for TB Drug Development<\/span><\/li><li><i class=\"tm-skincolor fa fa-arrow-circle-o-right\"><\/i>  <span class=\"tm-list-li-content\">University of Dundee, Drug Discovery Unit<\/span><\/li><\/ul>[\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;2998&#8243; img_size=&#8221;full&#8221;][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8221;1\/4&#8243; css=&#8221;.vc_custom_1610458272385{margin-top: -24px !important;}&#8221;][vc_column_text] ANTIMICROBIALS [\/vc_column_text][vc_wp_custommenu nav_menu=&#8221;33&#8243;][vc_single_image image=&#8221;2998&#8243;][\/vc_column][vc_column width=&#8221;3\/4&#8243;][vc_column_text]The ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative dedicated to accelerating the development of new TB treatment regimens, co-funded by the European programme H2020. The ERA4TB consortium consists of 31 partners from the European Union and the United States, including major global &hellip; <a href=\"https:\/\/genmico.unizar.es\/en\/d2amr-antimicrobials\/era4tb\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">ERA4TB<\/span><\/a><\/p>\n","protected":false},"author":31,"featured_media":0,"parent":2874,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/genmico.unizar.es\/en\/wp-json\/wp\/v2\/pages\/2994"}],"collection":[{"href":"https:\/\/genmico.unizar.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/genmico.unizar.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/genmico.unizar.es\/en\/wp-json\/wp\/v2\/users\/31"}],"replies":[{"embeddable":true,"href":"https:\/\/genmico.unizar.es\/en\/wp-json\/wp\/v2\/comments?post=2994"}],"version-history":[{"count":15,"href":"https:\/\/genmico.unizar.es\/en\/wp-json\/wp\/v2\/pages\/2994\/revisions"}],"predecessor-version":[{"id":3068,"href":"https:\/\/genmico.unizar.es\/en\/wp-json\/wp\/v2\/pages\/2994\/revisions\/3068"}],"up":[{"embeddable":true,"href":"https:\/\/genmico.unizar.es\/en\/wp-json\/wp\/v2\/pages\/2874"}],"wp:attachment":[{"href":"https:\/\/genmico.unizar.es\/en\/wp-json\/wp\/v2\/media?parent=2994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}